Separated pharmaceutical registration system should be limitedly applied.

The pharmaceutical industry took a cautious position on the amendment of the pharmaceutical affairs act covering the separated registration system applicable to the pharmaceutical business and products of the new chemical and BT drugs in fear of problems arising from the drug safety and market instability.

The industry said that unlike other common manufacturing commodities the drugs should ...